A US phase 2, multicenter, randomized controlled trial revealed that 2 years of moderate calorie restriction significantly reduced multiple cardiometabolic risk factors in young, non-obese adults. From May, 2007, to Feb, 2010, the trial randomly assigned 218 participants (21–50 years, BMI 22·0–27·9 kg/m 2) to a 25% calorie restriction diet (n=143) or an ad libitum control diet (n=75). Individuals in the calorie restriction group achieved a mean reduction in calorie intake of 11·9% (from 2467 kcal to 2170 kcal) versus 0·8% in the control group, and a sustained mean weight reduction of 7·5 kg versus an increase of 0·1 kg in the control group, of which 71% (mean change in fat mass 5·3 kg divided by mean change in weight 7·5 kg) was fat mass loss. Calorie restriction induced a persistent and significant reduction from baseline to 2 years of all measured conventional cardiometabolic risk factors, including change scores for LDL-cholesterol, total cholesterol to HDL-cholesterol ratio, and systolic and diastolic blood pressure. In addition, calorie restriction resulted in a significant improvement at 2 years in C-reactive protein, insulin sensitivity index, and metabolic syndrome score relative to control. A sensitivity analysis revealed the responses to be robust after controlling for relative weight loss changes. These findings suggest the potential for a substantial advantage for cardiovascular health of practicing moderate calorie restriction in young and middle-aged healthy individuals. Source: https://www.thelancet.com/
A study revealed that stroke remains a major global health challenge, influenced by numerous risk…
A systematic review and meta-analysis evaluated randomized controlled trials on pharmacological treatments for anxiety in…
A global study suggested that most patients with coronary heart disease (CHD) have Lipoprotein (a)…
A recent article explored the science and skepticism surrounding seed oils. These oils—extracted from sources…
A Canadian study of adults with high blood pressure (BP) found no difference in health…
Two randomized, controlled trials evaluated the efficacy and safety of obicetrapib, an oral cholesteryl ester…
This website uses cookies.